BIOLASE Reports Significantly Improved Revenue In Its Second Quarter As Continued High Demand For Dental Lasers From New Customers Fueled Growth
BIOLASE, Inc. (NASDAQ: BIOL) reported a robust second quarter of 2021, with net revenue soaring 211% to $9.1 million, significantly exceeding pre-pandemic levels. U.S. and international laser sales surged 299% and 806%, respectively, reflecting increased dental procedures post-COVID-19. Gross margin improved to 44%, up 1,200 basis points year-over-year. The net loss narrowed to $702,000 from $4.7 million a year earlier, aided by a $3 million PPP loan forgiveness. Looking ahead, BIOLASE anticipates significantly higher third-quarter revenue than the prior year, driven by sustained demand for dental lasers.
- Net revenue grew 211% to $9.1 million.
- U.S. laser sales increased by 299% year-over-year.
- International laser revenue surged 806% compared to the same quarter in 2020.
- Gross margin improved to 44%, up from 32% a year ago.
- Narrowed net loss to $702,000 from $4.7 million in the prior year.
- Strong cash position with $37.3 million as of June 30, 2021.
- Forecasts significantly above prior year Q3 revenue.
- Operating expenses rose to $7.3 million from $4.9 million in the previous year.
- Adjusted EBITDA loss remains at $2.7 million, although improved from $2.9 million.
FOOTHILL RANCH, Calif., Aug. 12, 2021 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for its second quarter ended June 30, 2021 and provided third quarter 2021 revenue guidance.
2021 Second Quarter Operating Highlights (all comparisons are on a year-over-year basis unless specified otherwise):
- Net revenue grew
211% to$9.1 million : - Over
70% of U.S. laser sales came from new customers, continuing a positive trend - Over
35% of U.S. Waterlase sales came from dental specialists - Net revenue was
6% higher than the pre-pandemic revenues during the second quarter of 2019 - Laser system sales increased
424% - Consumables and other revenue increased
173% - U.S. and international revenue increased
167% and340% , respectively, as more dental practices were operating during the 2021 second quarter compared to the year-ago second quarter due to the COVID-19 pandemic - Gross margin was
44% , up 1,200 basis points, due to the higher year-over-year revenue, favorable revenue mix and higher average selling prices for products sold during the quarter - Net loss was
$702,000 or$0.00 per share, compared to a net loss of$4.7 million or$0.12 per share a year ago - Maintained strong balance sheet, as cash and cash equivalents totaled
$37.1 million at quarter end
"Our strong second quarter performance is due to rising demand for our industry-leading dental lasers as a result of our intensified focus on education and training, the increased safety our lasers provide to dentists and their patients, and the published studies highlighting the improved results our laser provides to treat perio-disease," commented John Beaver, President and Chief Executive Officer.
"With over
"Our focus on educating and training dental specialists on the benefits of our lasers is already leading to increased adoption across these large and untapped markets. In fact, this momentum is giving us greater visibility into Q3, and we feel comfortable providing guidance regarding expected significant year-over-year improvement across our key performance metrics, including revenue and gross margin," concluded Mr. Beaver.
2021 Second Quarter Financial Results
Net revenue for the second quarter of 2021 was
Gross margin for the second quarter of 2021 was
Cash, cash equivalents, and restricted cash totaled
Adjusted EBITDA – Use of Non-GAAP Measures
The Reconciliation of GAAP Net Loss to Adjusted EBITDA at the end of this news release provides the details of the Company's non-GAAP disclosures and the reconciliation of GAAP net loss and net loss per share to the Company's Adjusted EBITDA and Adjusted EBITDA per share.
Adjusted EBITDA loss for the second quarter of 2021 was
2021 Third Quarter Revenue Guidance
The Company continues to experience high demand for its dental lasers and is currently forecasting revenue for the third quarter ending September 30, 2021, to be significantly above the year-ago third quarter despite the pent up demand the Company experienced in last year's Q3 as procedure volume dramatically improved from historically low levels in the 2020 second quarter. Even though the third quarter of the year is seasonally our second weakest revenue quarter, we expect the third quarter of 2021 to approach revenues we achieved in the second quarter of 2021.
Conference Call Information
BIOLASE, Inc. will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the second quarter ended June 30, 2021, and to answer questions. For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S./Canada is (800) 367-2403. For international participants outside the U.S./Canada, the dial-in number is (334) 777-6978. For all callers, refer to the Conference ID 9019839. To access the live webcast, visit the Investor Relations section of the BIOLASE website at www.biolase.com and see "Investor Events".
An audio archive of the webcast will be available for 30 days on the Investor Relations section of the BIOLASE website.
About BIOLASE
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 271 patented and 40 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, regarding the anticipated effects of our messaging, marketing, educational and training efforts; BIOLASE's expected revenue, revenue growth and gross margin for the third quarter of 2021; and anticipated cash needs. Forward-looking statements can be identified through the use of words such as may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "guidance," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the pandemic and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's most recent annual report filed on Form 10-K and quarterly report filed on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.
Tables to Follow
BIOLASE, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited, in thousands, except per share data) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Net revenue | $ | 9,134 | $ | 2,938 | $ | 17,250 | $ | 7,721 | ||||||||
Cost of revenue | 5,093 | 1,997 | 10,469 | 5,427 | ||||||||||||
Gross profit | 4,041 | 941 | 6,781 | 2,294 | ||||||||||||
Operating expenses: | ||||||||||||||||
Sales and marketing | 3,311 | 2,093 | 6,864 | 4,797 | ||||||||||||
General and administrative | 2,779 | 2,137 | 6,134 | 5,147 | ||||||||||||
Engineering and development | 1,162 | 690 | 2,966 | 1,680 | ||||||||||||
Loss on patent litigation settlement | 72 | — | 161 | — | ||||||||||||
Total operating expenses | 7,324 | 4,920 | 16,125 | 11,624 | ||||||||||||
Loss from operations | (3,283) | (3,979) | (9,344) | (9,330) | ||||||||||||
(Gain) Loss on foreign currency transactions | (69) | 40 | 136 | 126 | ||||||||||||
Interest expense, net | 582 | 625 | 1,157 | 1,214 | ||||||||||||
Gain on debt forgiveness | (3,014) | — | (3,014) | — | ||||||||||||
Non-operating (gain) loss, net | (2,501) | 665 | (1,721) | 1,340 | ||||||||||||
Loss before income tax provision (benefit) | (782) | (4,644) | (7,623) | (10,670) | ||||||||||||
Income tax provision (benefit) | (80) | 53 | (20) | 34 | ||||||||||||
Net loss | (702) | (4,697) | (7,603) | (10,704) | ||||||||||||
Other comprehensive loss items: | ||||||||||||||||
Foreign currency translation adjustments | 65 | 74 | (83) | 56 | ||||||||||||
Comprehensive loss | $ | (637) | $ | (4,623) | $ | (7,686) | $ | (10,648) | ||||||||
Net loss | $ | (702) | $ | (4,697) | $ | (7,603) | $ | (10,704) | ||||||||
Deemed dividend on convertible preferred stock | (6) | — | (538) | — | ||||||||||||
Net loss attributable to common stockholders | $ | (708) | $ | (4,697) | $ | (8,141) | $ | (10,704) | ||||||||
Net loss per share attributable to common stockholders: | ||||||||||||||||
Basic | $ | (0.00) | $ | (0.12) | $ | (0.06) | $ | (0.31) | ||||||||
Diluted | $ | (0.00) | $ | (0.12) | $ | (0.06) | $ | (0.31) | ||||||||
Shares used in the calculation of net loss per share: | ||||||||||||||||
Basic | 150,665 | 37,990 | 142,693 | 34,709 | ||||||||||||
Diluted | 150,665 | 37,990 | 142,693 | 34,709 | ||||||||||||
BIOLASE, INC. CONSOLIDATED BALANCE SHEETS (Unaudited, in thousands, except per share data) | ||||||||
June 30, | December 31, | |||||||
2021 | 2020 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 37,081 | $ | 17,564 | ||||
Restricted cash | 204 | 312 | ||||||
Accounts receivable, less allowance of | 3,819 | 3,059 | ||||||
Inventory | 12,715 | 11,157 | ||||||
Prepaid expenses and other current assets | 1,521 | 3,018 | ||||||
Total current assets | 55,340 | 35,110 | ||||||
Property, plant, and equipment, net | 916 | 782 | ||||||
Goodwill | 2,926 | 2,926 | ||||||
Right of use asset | 1,842 | 1,976 | ||||||
Other assets | 225 | 231 | ||||||
Total assets | $ | 61,249 | $ | 41,025 | ||||
LIABILITIES, REDEEMABLE PREFERRED STOCK AND | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 3,502 | $ | 2,651 | ||||
Accrued liabilities | 6,461 | 6,667 | ||||||
Deferred revenue, current portion | 2,056 | 1,905 | ||||||
Term loan, net of discount | 700 | — | ||||||
Total current liabilities | 12,719 | 11,223 | ||||||
Deferred revenue | 333 | 374 | ||||||
Warranty accrual | 507 | 384 | ||||||
Non current term loans, net of discount | 12,703 | 16,186 | ||||||
Non current operating lease liability | 1,602 | 1,774 | ||||||
Other liabilities | 129 | 1,056 | ||||||
Total liabilities | 27,993 | 30,997 | ||||||
Stockholders' equity: | ||||||||
Series F Preferred stock, par value | 35 | 118 | ||||||
Common stock, par value | 151 | 98 | ||||||
Additional paid-in capital | 292,517 | 261,573 | ||||||
Accumulated other comprehensive loss | (468) | (385) | ||||||
Accumulated deficit | (258,979) | (251,376) | ||||||
Total stockholders' equity | 33,256 | 10,028 | ||||||
Total liabilities, redeemable preferred stock and stockholders' equity | $ | 61,249 | $ | 41,025 | ||||
BIOLASE, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited, in thousands) | ||||||||
Six Months Ended | ||||||||
June 30, | ||||||||
2021 | 2020 | |||||||
Cash Flows from Operating Activities: | ||||||||
Net loss | $ | (7,603) | $ | (10,704) | ||||
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities: | ||||||||
Depreciation and amortization | 176 | 488 | ||||||
Provision for bad debts | (79) | 1,008 | ||||||
Inventory write-offs and disposals | (103) | — | ||||||
Amortization of discount on lines of credit | 84 | 74 | ||||||
Amortization of debt issuance costs | 193 | 121 | ||||||
Patent litigation mark-to-market | 161 | — | ||||||
Stock-based compensation | 1,297 | 1,519 | ||||||
Gain on debt forgiveness | (3,014) | — | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | (682) | 3,633 | ||||||
Inventory | (1,455) | (937) | ||||||
Prepaid expenses and other current assets | 438 | (14) | ||||||
Accounts payable and accrued liabilities | 471 | (3,835) | ||||||
Deferred revenue | 108 | (692) | ||||||
Net cash and cash equivalents used in operating activities | (10,008) | (9,339) | ||||||
Cash Flows from Investing Activities: | ||||||||
Purchases of property, plant, and equipment | (311) | (81) | ||||||
Net cash and cash equivalents used in investing activities | (311) | (81) | ||||||
Cash Flows from Financing Activities: | ||||||||
Proceeds from the sale of common stock | 13,291 | 3,881 | ||||||
Proceeds from the sale of common stock warrants | — | 3,031 | ||||||
Payments of equity offering costs | (6) | (991) | ||||||
Borrowings on other long-term loans | — | 3,140 | ||||||
Borrowings on credit facility | — | 3,000 | ||||||
Repayment of credit facility | — | (3,000) | ||||||
Fees paid for debt instruments | — | (50) | ||||||
Proceeds from the exercise of common stock warrants | 16,550 | — | ||||||
Payment of debt issuance costs | (24) | — | ||||||
Net cash and cash equivalents provided by financing activities | 29,811 | 9,011 | ||||||
Effect of exchange rate changes | (83) | 57 | ||||||
Increase (decrease) in cash, cash equivalents and restricted cash | 19,409 | (352) | ||||||
Cash, cash equivalents and restricted cash, beginning of period | 17,876 | 6,101 | ||||||
Cash, cash equivalents and restricted cash, end of period | $ | 37,285 | $ | 5,749 | ||||
Supplemental cash flow disclosure: | ||||||||
Cash paid for interest | $ | 886 | $ | 466 | ||||
Cash received for interest | $ | 29 | $ | — | ||||
Cash paid for income taxes | $ | 130 | $ | 26 | ||||
Cash paid for operating leases | $ | 263 | $ | 188 | ||||
Non-cash accrual for capital expenditures | $ | — | $ | 35 | ||||
Non-cash settlement of liability | $ | 510 | $ | — | ||||
Non-cash right-of-use assets obtained in exchange for lease obligation | $ | 48 | $ | 570 | ||||
Warrants issued in connection with debt instruments | $ | — | $ | 67 | ||||
Non-GAAP Financial Measures
In addition to the financial information prepared in conformity with generally accepted accounting principles in the U.S. ("GAAP"), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company's ongoing core operating performance than their GAAP equivalents.
Adjusted EBITDA is defined as net income (loss) before interest, taxes, depreciation and amortization, loss on patent litigation settlement, stock-based and other non-cash compensation, debt forgiveness, and allowance for doubtful accounts. Management uses Adjusted EBITDA in its evaluation of the Company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.
BIOLASE, INC. Reconciliation of GAAP Net Loss to Adjusted EBITDA and GAAP Net Loss Per Share to Adjusted EBITDA Per Share (Unaudited, in thousands, except per share data) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
GAAP net loss attributable to common stockholders | $ | (708) | $ | (4,697) | $ | (8,141) | $ | (10,704) | ||||||||
Deemed dividend on convertible preferred stock | 6 | — | 538 | — | ||||||||||||
GAAP net loss | $ | (702) | $ | (4,697) | $ | (7,603) | $ | (10,704) | ||||||||
Adjustments: | ||||||||||||||||
Interest expense, net | 582 | 625 | 1,157 | 1,214 | ||||||||||||
Income tax provision (benefit) | (80) | 53 | (20) | 34 | ||||||||||||
Depreciation and amortization | 91 | 307 | 176 | 488 | ||||||||||||
Change in allowance for doubtful accounts | 27 | 22 | (79) | 1,008 | ||||||||||||
Loss on patent litigation settlement | 72 | — | 161 | — | ||||||||||||
Stock-based and other non-cash compensation | 369 | 801 | 1,297 | 1,519 | ||||||||||||
Gain on debt forgiveness | (3,014) | — | (3,014) | — | ||||||||||||
Adjusted EBITDA | $ | (2,655) | $ | (2,889) | $ | (7,925) | $ | (6,441) | ||||||||
GAAP net loss attributable to common stockholders | $ | — | $ | (0.12) | $ | (0.06) | $ | (0.31) | ||||||||
Deemed dividend on convertible preferred stock | — | — | — | — | ||||||||||||
GAAP net loss per share, basic and diluted | $ | — | $ | (0.12) | $ | (0.06) | $ | (0.31) | ||||||||
Adjustments: | ||||||||||||||||
Interest expense, net | — | 0.02 | 0.01 | 0.03 | ||||||||||||
Income tax provision (benefit) | — | — | — | — | ||||||||||||
Depreciation and amortization | — | 0.01 | — | 0.01 | ||||||||||||
Change in allowance for doubtful accounts | — | — | — | 0.03 | ||||||||||||
Loss on patent litigation settlement | — | — | — | — | ||||||||||||
Stock-based and other non-cash compensation | — | 0.01 | 0.02 | 0.05 | ||||||||||||
Gain on debt forgiveness | (0.02) | — | (0.02) | — | ||||||||||||
Adjusted EBITDA per share, basic and diluted | $ | (0.02) | $ | (0.08) | $ | (0.05) | $ | (0.19) | ||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-reports-significantly-improved-revenue-in-its-second-quarter-as-continued-high-demand-for-dental-lasers-from-new-customers-fueled-growth-301354660.html
SOURCE BIOLASE, Inc.
FAQ
What were BIOL's second quarter 2021 financial results?
How much did U.S. laser sales increase in the second quarter of 2021?
What is the expected revenue guidance for BIOLASE in the third quarter of 2021?
How did BIOLASE's gross margin change in the second quarter of 2021?
What was the net loss for BIOLASE in the second quarter of 2021?
